Albany Molecular Research, Seattle Genetics deal

The companies expanded a 2002 deal to develop and manufacture SGEN's drug-linker systems for its antibody-drug conjugate (ADC) technology (see BioCentury, Oct. 14, 2002). As expanded, AMRI will be a p...